peptideone
← All peptides

Gonadorelin

Status unknown

Also known as: Gonadorelina, GnRH-I, 33515-09-2, Gonadorelinum, Fertagyl, LH-Releasing factor, Luforan, Lutrefact

Gonadorelin (Gonadorelina, GnRH-I, 33515-09-2) is classified under reproductive & hypothalamic peptides.

What the research says

Aggregated from the cited literature below. We summarize sources — we don't author claims.

Gonadorelin (also referred to as GnRH-I and LH-releasing factor) is discussed in the provided literature as a small peptide hormone/neuropeptide involved in neuroendocrine regulation, with research coverage including analytical methods and broader reproductive-axis biology. It is also mentioned in contexts involving misuse for anti-doping and as a peptide target/analogue class in disease-related reviews.

Mechanism (as reported)

A review of reproductive neuroendocrine regulation describes GnRH as a primary regulator of the hypothalamic–pituitary axis, controlling luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion through pulsatile GnRH release patterns. (PMID: 38778605)

Key findings (each cites a source)

  • A review described advances in analytical technology for small peptide hormones and provided a case focused on gonadorelin, discussing analytical approaches including chromatography, immunochemistry, and affinity sensing, and noting trends toward simpler, on-site, faster, and lower-cost analyses. [PMID 36858006]
  • The same analytical-technology review described gonadorelin as a neuropeptide that has drawn attention as a therapeutic drug misused for doping practices during sports competitions. [PMID 36858006]
  • A review of infertility management described GnRH as a primary reproductive-axis regulator, regulating secretion of LH and FSH, and stated that the pattern of GnRH release is pulsatile and controls endocrine function and gamete maturation. [PMID 38778605]
  • A review on infertility-related peptide targets described other peptides (Kisspeptin, Neurokinin-B, Orexin) as influencing positive and negative feedback modulation of GnRH, FSH, and LH secretion, and referenced clinical and preclinical studies in infertility management. [PMID 38778605]
  • An oncology review discussed peptide analogs targeting LH-RH in prostate cancer, including depot preparations of LH-RH agonists as a preferred primary treatment approach in advanced androgen-dependent disease and mentions LH-RH antagonists in clinical trials. [PMID 11027415]

Independent test grades

No independent third-party test data is available for Gonadorelin yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.

Research literature (8)

Consolidated from PubMed — each links to the original record.

FAQ

What is Gonadorelin?
Gonadorelin (Gonadorelina, GnRH-I, 33515-09-2) is classified under reproductive & hypothalamic peptides. Research goals associated with it include sexual & reproductive.
Is Gonadorelin FDA-approved?
The regulatory status of Gonadorelin is not established in our sources.
What does the research on Gonadorelin say?
peptideone aggregates 8 references from PubMed for Gonadorelin. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.
Aggregated from public sources, with attribution. Not medical advice; compounds discussed are not approved for human consumption. Last updated 2026-06-15.